Firefly Neuroscience Inc is an artificial intelligence company advancing precision neuroscience, applying AI and large-scale electrophysiological data to give clinicians a more complete, objective picture of how an individual patient's brain is functioning. The firm is developing neuroscientific solutions that improve outcomes for patients with mental illnesses and cognitive disorders. It is focused on the commercialization of its Brain Network Analytics (BNA) software platform (the "BNA Platform")and the discovery and clinical development of biomarkers that support outcomes for people suffering from mental illnesses and cognitive disorders. The company has one reportable segment: the BNA platform. The Company derives revenue from North America.
Last trade$0.9046
Day change+$0.0193 (+2.18%)
Day range$0.885 – $1.01
Volume126,041
Market cap$14M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$14.02M
Price / earnings
—
Price / book
1.04×
Price / sales
6.81×
EV / sales
2.91×
EV / EBITDA
-0.77×
Profitability
Earnings per share
-$0.53
Return on assets
-53.57%
Return on equity
-61.63%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
4.48×
Quick ratio
4.45×
Cash ratio
3.97×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$6.83M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for AIFF, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$647K
$514K
$485K
$412K
$388K
$299K
$43K
$53K
Cost of revenue
$122K
$261K
$264K
$230K
$242K
$25K
$0
$0
Gross profit
$525K
$253K
$221K
$182K
$146K
$274K
$43K
$53K
Selling, general and administrative
$1.68M
$1.7M
$1.81M
$2.13M
$2.27M
$1.57M
$1.8M
$2.18M
Research and development
$383K
$525K
$424K
$456K
$378K
$336K
$312K
$437K
Total operating expenses
$2.07M
$2.23M
$2.23M
$2.68M
$2.8M
$1.91M
$2.11M
$3.49M
Operating income
-$1.54M
-$1.97M
-$2.01M
-$2.5M
-$2.66M
-$1.63M
-$2.07M
-$3.44M
Interest expense
-$4K
-$6K
-$7K
-$6K
-$10K
-$15K
-$128K
-$33K
Income before taxes
-$1.48M
-$1.98M
-$2M
-$2.48M
-$2.64M
-$1.83M
-$12.93M
-$3.78M
Income taxes
$0
$0
$0
$1K
$0
$4K
$0
-$2K
Net income
-$1.48M
-$1.98M
-$2M
-$2.48M
-$2.64M
-$1.83M
-$12.93M
-$3.78M
Net income attributable to common shareholders
-$1.48M
-$1.98M
-$2.09M
-$2.72M
-$2.64M
-$1.83M
-$17.34M
-$3.79M
EBITDA
-$1.49M
-$1.93M
-$1.97M
-$2.35M
-$2.45M
-$1.59M
-$2.05M
-$2.5M
Basic earnings per share
-$0.07
-$0.10
-$0.13
-$0.20
-$0.20
-$0.14
-$1.74
-$0.43
Diluted earnings per share
-$0.07
-$0.10
-$0.13
-$0.20
-$0.20
-$0.14
-$1.74
-$0.43
Recent news
Company coverage with links to the original publishers.
Firefly Neuroscience announced a nearly four-fold increase in TMS center customer clinical assessments using its FDA-cleared Evoke AI-powered EEG/ERP platform. The platform combines quantitative EEG and event-related potentials to help clinicians assess brain activity and tailor treatments for psychiatric and behavioral health conditions. The company continues to expand adoption among TMS centers while building its proprietary database of over 200,000 EEG/ERP brain scans.
Firefly Neuroscience (NASDAQ: AIFF) and Next Health announced a strategic partnership to launch a precision cognitive health platform combining Firefly's FDA-cleared AI-powered EEG/ERP brain biomarker technology with personalized cognitive peptide protocols. The collaboration follows an FDA Advisory Committee's recommendation to ease compounding restrictions for six peptides, including Epitalon and Semax, which have shown potential neuroprotective and cognitive-supportive properties in scientific literature.
Firefly Neuroscience researchers have developed a new method to accurately differentiate between subjective cognitive decline (SCD), mild cognitive impairment (MCI), and dementia in Alzheimer's patients using a combination of EEG/ERP and volumetric MRI data.
Firefly Neuroscience, an AI company, has acquired Evoke Neuroscience, a medical device company, to expand its proprietary database, patent portfolio, and commercial reach. The acquisition marks a significant step towards Firefly's goal of building a foundation model of the human brain.
Firefly Neuroscience, Inc. has received $8.8 million from the exercise of warrants, which will be used for general working capital purposes, including the development of its FDA-cleared Brain Network Analytics (BNA™) technology platform.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.